These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 24112719

  • 1. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

  • 2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Dec; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 3. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A.
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [Abstract] [Full Text] [Related]

  • 7. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.
    Clin Cancer Res; 2012 May 01; 18(9):2603-12. PubMed ID: 22407832
    [Abstract] [Full Text] [Related]

  • 8. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.
    Breast Cancer Res; 2011 Mar 01; 13(6):R121. PubMed ID: 22123186
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.
    PLoS One; 2010 Feb 02; 5(2):e9024. PubMed ID: 20126311
    [Abstract] [Full Text] [Related]

  • 20. AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.
    Buccinnà B, Ramondetti C, Piccinini M.
    Biochem Pharmacol; 2022 Oct 02; 204():115228. PubMed ID: 36007575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.